透析患者心血管事件诊治进展

doi:10.3969/j.issn.1671-4091.2021.07.001

摘要/Abstract

摘要： 【摘要】我国血液透析及腹膜透析患者数量逐年增多，透析患者心血管疾病(cardiovascular disease，CVD)高发且死亡率高。本文主要关注透析患者心血管事件包括冠状动脉粥样硬化性心脏病(coronary atherosclerotic disease，CAD)及心力衰竭。透析患者CAD 诊治原则与非肾病患者相似，部分检查、治疗、用药的指征、效果和副作用具有透析患者的特异性。

关键词: 血液透析, 腹膜透析, 心血管事件, 冠状动脉粥样硬化性心脏病, 心力衰竭

Abstract: 【Abstract】The number of hemodialysis and peritoneal dialysis patients increase yearly in China. The incidence of cardiovascular disease (CVD) is higher in dialysis patients, causing higher mortality in these patients. This article focuses on CVD, including coronary atherosclerotic heart disease and heart failure, in dialysis patients. The principles of diagnosis and management of CVD in dialysis patients are similar to those in non-renal patients. However, some of the examinations, treatment indicators and effects, and medication side effects are specific to dialysis patients.

Key words: Hemodialysis, Peritoneal dialysis, Cardiovascular disease, Coronary artery disease, Heart failure

中图分类号:

朱新旺, 徐天华, 姚丽. 透析患者心血管事件诊治进展[J]. 中国血液净化, 2021, 20(07): 433-436.

参考文献

[1]ZHANG L, ZHAO M-H, LI ZUO, et al.China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J].Kidney international supplements, 2019, 9(1):e1-e81 [2]Saran, Rajiv; Robinson, Bruce; Abbott, Kevin C.; Bragg-Gresham, Jennifer; Chen, Xiaoying; Gipson, Debbie; Gu, Haoyu; Hirth, Richard A.; Hutton, David; Jin, Yan; Kapke, Alissa; Kurtz, Vivian; Li, Yiting; McCullough, Keith; Modi, Zubin; Morgenstern, Hal; Mukhopadhyay, Purna; Pearson, Jeffrey; Pisoni, Ronald; Repeck, Kaitlyn; Schaubel, Douglas E.; Shamraj, Ruth; Steffick, Diane; Turf, Megan; Woodside, Kenneth J.; Xiang, Jie; Yin, Maggie; Zhang, Xiaosong; Shahinian, Vahakn.US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States[J]. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019.[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, 75(1 Suppl 1):A6-A7 [3]CHEUNG A K, SARNAK M J, YAN G, et al.Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study[J].Kidney international, 2004, 65(6):2380-2389 [4]STACK A G, BLOEMBERGEN W E.Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study[J].Journal of the American Society of Nephrology : JASN, 2001, 12(7):1516-1523 [5]FOLEY R N, PARFREY P S.Cardiac disease in chronic uremia: clinical outcome and risk factors[J].Advances in renal replacement therapy, 1997, 4(3):234-248 [6]FUNG F, SHERRARD D J, GILLEN D L, et al.Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, 40(2):307-314 [7]JUG B, PAPAZIAN J, GUPTA M, et al.Diagnostic performance of computed tomographic coronary angiography in patients with end-stage renal disease[J].Coronary artery disease, 2013, 24(2):135-141 [8]OHTAKE T, KOBAYASHI S, MORIYA H, et al.High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination[J].Journal of the American Society of Nephrology : JASN, 2005, 16(4):1141-1148 [9]KHAN N A, HEMMELGARN B R, TONELLI M, et al.Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis[J].Circulation, 2005, 112(20):3088-3096 [10]JUG B, PAPAZIAN J, GUPTA M, et al.Diagnostic performance of computed tomographic coronary angiography in patients with end-stage renal disease[J].Coronary artery disease, 2013, 24(2):135-141 [11]FERRO C J, MARK P B, KANBAY M, et al.Lipid management in patients with chronic kidney disease[J].Nature reviews. Nephrology, 2018, 14(12):727-749 [12]Wanner, Christoph; Tonelli, Marcello.KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient[J].Kidney international, 2014, 85(6):1303-1309 [13]MACH F, BAIGENT C, CATAPANO A L, et al.ESCEAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J].European heart journal, 2020, 41(1):111-188 [14]PATRICK B MARK1 AND PETER WINOCOUR2.Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease[J]. ABCD-RA, 2017.[J].ABCD-RA, 2017, 1(1):1-26 [15]HEMMELGARN B R, SOUTHERN D, CULLETON B F, et al.Survival after coronary revascularization among patients with kidney disease[J].Circulation, 2004, 110(14):1890-1895 [16]ROBERTS J K, PATEL U D.Management of coronary artery disease in end-stage renal disease[J].Seminars in dialysis, 2011, 24(5):525-532 [17]L?FMAN I, SZUMMER K, DAHLSTR?M U, et al.Associations with and prognostic impact of chronic kidney disease in heart failure with preserved,mid-range,and reduced ejection fraction[J].European journal of heart failure, 2017, 19(12):1606-1614 [18]EDWARDS N C, MOODY W E, CHUE C D, et al.Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance[J].JACC. Cardiovascular imaging, 2014, 7(7):703-714 [19]SARAN R, ROBINSON B, ABBOTT K C, et al.US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, 69(3 Suppl 1):A7-A8 [20]WANG A Y-M, WANG M, LAM C W-K, et al.Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis[J].Clinical journal of the American Society of Nephrology : CJASN, 2011, 6(4):805-812 [21]BANERJEE D, MA J Z, COLLINS A J, et al.Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure,pulmonary edema,or fluid overload[J].Clinical journal of the American Society of Nephrology : CJASN, 2007, 2(6):1186-1190 [22]PANIAGUA R, VENTURA M-J, AVILA-DíAZ M, et al.NT-proBNP,fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients[J].Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, 25(2):551-557 [23]TUEGEL C, KATZ R, ALAM M, et al.GDF-15,Galectin 3,Soluble ST2,and Risk of Mortality and Cardiovascular Events in CKD[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, 72(4):519-528 [24]MCCULLOUGH P A, OLOBATOKE A, VANHECKE T E.Galectin-3: a novel blood test for the evaluation and management of patients with heart failure[J].Reviews in cardiovascular medicine, 2011, 12(4):200-210 [25]MUELLER-LENKE N, RUDEZ J, STAUB D, et al.Use of chest radiography in the emergency diagnosis of acute congestive heart failure[J].Heart (British Cardiac Society), 2006, 92(5):695-696 [26]PARK J H, JO Y-I, LEE J-H.Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis[J].The Korean journal of internal medicine, 2018, 33(4):660-669 [27]KOTT J, REICHEK N, BUTLER J, et al.Cardiac Imaging in Dialysis Patients[J].Kidney medicine, 2020, 2(5):629-638 [28]CHAWLA L S, HERZOG C A, COSTANZO M R, et al.Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup[J].Journal of the American College of Cardiology, 2014, 63(13):1246-1252 [29]Upadhya, Bharathi; Rocco, Michael; Lewis, Cora E.; Oparil, Suzanne; Lovato, Laura C.; Cushman, William C.; Bates, Jeffrey T.; Bello, Natalie A.; Aurigemma, Gerard; Fine, Lawrence J.; Johnson, Karen C.; Rodriguez, Carlos J.; Raj, Dominic S.; Rastogi, Anjay; Tamariz, Leonardo; Wiggers, Alan; Kitzman, Dalane W..Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial[J].Circulation. Heart failure, 2017, 10(4):1-10 [30]RAHMAN M, FORD C E, CUTLER J A, et al.Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR[J].Clinical journal of the American Society of Nephrology : CJASN, 2012, 7(6):989-1002 [31]INRIG J K, PATEL U D, GILLESPIE B S, et al.Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2007, 50(1):108-18 [32]AGARWAL R, ALBORZI P, SATYAN S, et al.Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized,controlled trial[J].Hypertension (Dallas, Tex.), 2009, 53(3):500-507 [33]LEON S J, TANGRI N.The Use of Renin-Angiotensin System Inhibitors in Patients WithChronic Kidney Disease[J].The Canadian journal of cardiology, 2019, 35(9):1220-1227 [34]QIAO Y, SHIN J-I, CHEN T K, et al.Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate[J].JAMA internal medicine, 2020, 180(5):718-726 [35]He, Jiang; Shlipak, Michael; Anderson, Amanda; Roy, Jason A.; Feldman, Harold I.; Kallem, Radhakrishna Reddy; Kanthety, Radhika; Kusek, John W.; Ojo, Akinlolu; Rahman, Mahboob; Ricardo, Ana C.; Soliman, Elsayed Z.; Wolf, Myles; Zhang, Xiaoming; Raj, Dominic; Hamm, Lee.Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study[J].Journal of the American Heart Association, 2017, 6(5):1-10 [36]PERKOVIC V, JARDINE M J, NEAL B, et al.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J].The New England journal of medicine, 2019, 380(24):2295-2306 [37]NEUEN B L, YOUNG T, HEERSPINK H J L, et al.SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis[J].The lancet. Diabetes & endocrinology, 2019, 7(11):845-854 [38]ZELNIKER T A, WIVIOTT S D, RAZ I, et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J].The Lancet, 2019, 393(10166):31-39 [39]GHALI J K, WIKSTRAND J, VAN VELDHUISEN D J, et al.The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CRXL Randomized Intervention Trial in Chronic HF (MERIT-HF)[J].Journal of cardiac failure, 2009, 15(4):310-318 [40]Philippe Lechat.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial[J].The Lancet, 1999, 353(9146):9-13 [41]WEIR M A, DIXON S N, FLEET J L, et al.Blocker dialyzability and mortality in older patients receiving hemodialysis[J].Journal of the American Society of Nephrology : JASN, 2015, 26(4):987-996 [42]PITT B, PFEFFER M A, ASSMANN S F, et al.Spironolactone for heart failure with preserved ejection fraction[J].The New England journal of medicine, 2014, 370(15):1383-1392 [43]CHUA D, LO A, LO C.Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?[J].Clinical cardiology, 2010, 33(10):604-608 [44]MATSUMOTO Y, MORI Y, KAGEYAMA S, et al.Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients[J].Journal of the American College of Cardiology, 2014, 63(6):528-536 [45]TRINH E, BARGMAN J M.Are Diuretics Underutilized in Dialysis Patients?[J].Seminars in dialysis, 2016, 29(5):338-341 [46]KIM Y-L, VAN BIESEN W.Fluid Overload in Peritoneal Dialysis Patients[J].Seminars in nephrology, 2017, 37(1):43-53 [47]MCMURRAY J J V, PACKER M, DESAI A S, et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].The New England journal of medicine, 2014, 371(11):993-1004 [48]SOLOMON S D, MCMURRAY J J V, ANAND I S, et al.Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J].The New England journal of medicine, 2019, 381(17):1609-1620 [49]HAYNES R, JUDGE P K, STAPLIN N, et al.Effects of SacubitrilValsartan Versus Irbesartan in Patients With Chronic Kidney Disease[J].Circulation, 2018, 138(15):1505-1514 [50]LEE S, OH J, KIM H, et al.Sacubitrilvalsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J].ESC heart failure, 2020, 7(3):1125-1129 [51]AUSTIN G STACK 1, DONALD A MOLONY, NOOR S RAHMAN, AKINSANSOYE DOSEKUN, BHAMIDIPATI MURTHY.Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States[J].Kidney international, 2003, 64(3):1071-1079 [52]MCCULLOUGH P A, CHAN C T, WEINHANDL E D, et al.Intensive Hemodialysis,Left Ventricular Hypertrophy,and Cardiovascular Disease[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, 68(5S1):S5-S14